PEDF expression is inhibited by insulin treatment in adipose tissue via suppressing 11β-HSD1

Yinli Zhou1, Fen Xu1, Hongrong Deng1

  • 1Department of Endocrinology and Metabolism, the Third Affiliated Hospital of Sun Yat-Sen University; Key Laboratory of Diabetology of Guangdong Province, Guangzhou, China.

Plos One
|December 25, 2013
PubMed

Insights

Insulin therapy in type 2 diabetes reduces Pigment epithelium-derived factor (PEDF) by targeting the 11β-HSD1/glucocorticoid pathway in adipose tissue, improving insulin resistance.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Metabolic Diseases

Background:

  • Insulin resistance in type 2 diabetes is a complex condition with incompletely understood mechanisms.
  • Pigment epithelium-derived factor (PEDF), an anti-angiogenic factor, is implicated in the pathogenesis of insulin resistance.

Purpose of the Study:

  • To investigate the regulation of PEDF by insulin in type 2 diabetic conditions.
  • To elucidate the molecular pathways linking insulin therapy, PEDF, and insulin sensitivity.

Main Methods:

  • Analysis of serum PEDF levels in type 2 diabetic patients before and after insulin therapy.
  • Investigation of PEDF expression in adipose tissue of diabetic rats.
  • In vitro studies using adipocytes to examine the roles of TNF-α, NF-κB, 11β-HSD1, and glucocorticoids in PEDF regulation.

Main Results:

  • Serum PEDF decreased by 15% after insulin therapy in newly diagnosed type 2 diabetic patients.
  • Insulin treatment reduced PEDF in serum and adipose tissue of diabetic rats.
  • In adipocytes, TNF-α induced PEDF via NF-κB activation, which in turn promoted 11β-HSD1 expression, leading to increased PEDF. Insulin inhibited PEDF by down-regulating 11β-HSD1.

Conclusions:

  • PEDF expression in adipose tissue of diabetic patients is upregulated by inflammation (TNF-α) and downregulated by insulin.
  • Insulin improves insulin sensitivity by reducing PEDF through the 11β-HSD1/glucocorticoid pathway in adipose tissue.

Related Concept Videos

Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.3K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
6.0K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K